Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study

Alexandre de Nonneville (1) , Anthony Gonçalves (2) , Christophe Zemmour (1) , Jean Classe , Monique Cohen (3) , Eric Lambaudie (4) , Fabien Reyal (5) , Christophe Scherer , Xavier Muracciole (6) , Pierre Colombo , Sylvia Giard (7) , Roman Rouzier (8) , Richard Villet (9) , Nicolas Chopin (10) , Emile Darai (8) , Jean Garbay , Pierre Gimbergues (11) , Laura Sabiani (12) , Charles Coutant (13) , Renaud Sabatier (1) , François Bertucci (1) , Jean Boher , Gilles Houvenaeghel

1 CRCM - Centre de Recherche en Cancérologie de Marseille
2 IPC - Institut Paoli-Calmettes
3 La Casamance
4 Service d'Oncologie Chirurgicale
5 U932 - Immunité et cancer
6 Service d’Oncologie Médicale [Hôpital de la Timone - APHM]
7 UNICANCER/Lille - Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille]
8 CHU Tenon [AP-HP]
9 Groupe Hospitalier Diaconesses Croix Saint-Simon
10 CREST - Centre de Recherche en Économie et Statistique
11 UNICANCER/CJP - Centre Jean Perrin [Clermont-Ferrand]
12 APHM - Assistance Publique - Hôpitaux de Marseille
13 UNICANCER/CRLCC-CGFL - Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon]

Domaines: Cancer

Alexandre de Nonneville, Anthony Gonçalves, Christophe Zemmour, Jean Classe, Monique Cohen, et al.. Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study. Breast Cancer Research and Treatment, 2017, 162 (2), pp.307-316. ⟨10.1007/s10549-017-4136-5⟩. ⟨hal-03623719⟩